CB1 Pharmacy and Glass Pharms have announced a new supply agreement for Cannabis-Based Products for Medicinal Use in humans (CBPM). The agreement, which was finalized on Thursday 7 August, 2025, follows a successful period of patient feedback and will provide UK patients with more affordable and accessible options for medical cannabis treatment.
The CBPMs will be derived from Glass Pharms’ UK-grown medical cannabis flower and will be supplied through Xeal Pharma. In addition to the Glass Pharms products already prescribed, CB1 Pharmacy will also offer EcoCann Access for eligible patients. This range will provide cost-effective options for patients with a fully UK-based supply chain, open to all patients registered with any current access scheme.
CB1 Medical, known for its patient-led care model, is the launch partner for the EcoCann Access range. The products will be organized around cannabis phenotypes, rather than individual cultivars, to offer prescribing options that are easier for patients and clinicians to navigate.
“We see the importance of a UK-based supply chain and we are happy to partner with Glass Pharms on a range of products derived from their flower that will increase accessibility and choice for UK patients,” said Professor Rishabh Prasad, Founder of CB1 Medical.
The EcoCann Access range will include Sativa, Indica, and Balanced Hybrid types, providing clinicians with the option to maintain a continuity across phenotype. The specific cannabis cultivars used will be listed for patient and clinician information.
James Duckenfield, CEO of Glass Pharms, explained the use of phenotypes in determining the general indication of a cannabis-based medicine. “Although cannabis phenotypes are not an exact science and the vast majority of contemporary cannabis cultivars are not purely either Sativa or Indica, using phenotypes is still a useful way of determining the general indication of a cannabis-based medicine,” he said. “These are often described as ‘day-time’ and ‘night-time’ options by patients and clinicians.”
The EcoCann Access range will offer a simpler option for patients and clinicians who may find the world of cannabis cultivar names confusing. “Having seen Glass Pharms myself, I can say that they use the most robust processes to maintain the highest quality medicine produced,” added Irfan Abdulla, CB1 Pharmacy’s Superintendent Pharmacist.
Glass Pharms is a leading cultivator of medical cannabis, using a custom-built 2.4-hectare greenhouse facility in the West of England that is powered entirely by food waste. Their sustainability profile is best-in-class, with power and heat for the site coming from supermarket and household food waste used by the adjoining anaerobic digestion plant.
CB1 Medical, known as the ‘UK’s most affordable medical cannabis clinic’, is a fast-growing private medical cannabis clinic that prioritizes patient needs. For more information, visit https://glasspharms.com/ and https://cb1medical.com/. For any inquiries, please contact info@glasspharms.com.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.